• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Cytovale Secures $100M to Expand Commercialization of FDA-Cleared Sepsis Test

by Fred Pennic 10/11/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Cytovale, a medical diagnostics company revolutionizing early disease detection secures $100M in Series D funding round led by Sands Capital with participation from new investor Canada Pension Plan Investment Board (CPP Investments) and existing investors. 

–  The investment will fuel the expansion of Cytovale’s innovative sepsis diagnostic, IntelliSep, to more hospital emergency departments (EDs) and health systems nationwide.

IntelliSep: Transforming Sepsis Detection in the Emergency Department

Sepsis, a life-threatening condition caused by the body’s overwhelming response to infection, often presents in the emergency department (ED). IntelliSep is the first and only FDA-cleared cellular host diagnostic specifically designed for use in the ED, where over 80% of sepsis cases initially appear.

This innovative test provides clinicians with a unique window into the biological mechanisms driving sepsis, enabling rapid and confident diagnosis. With results available in approximately eight minutes, IntelliSep empowers care teams to deliver timely and targeted treatment, potentially saving lives.

Early Success and Improved Outcomes

Since its launch in August 2023, IntelliSep has demonstrated significant clinical impact. Our Lady of the Lake Regional Medical Center in Baton Rouge, Louisiana, an early adopter of the technology, has reported impressive results:

  • Faster Treatment: Earlier detection of sepsis through IntelliSep has led to treatment initiation more than 60 minutes faster.
  • Reduced Mortality: The hospital observed a 30% decrease in the risk-adjusted mortality index for sepsis patients.
  • Shorter Hospital Stays: Patients tested with IntelliSep spent 1.28 fewer days in the hospital.
  • Cost Savings: The hospital realized a savings of $1,400 per patient tested with IntelliSep.

Expanding Access to Life-Saving Technology

This new funding will enable Cytovale to:

  • Accelerate Commercial Expansion: Bring IntelliSep to more hospital EDs and health systems nationwide, increasing access to this life-saving diagnostic tool.
  • Build on Clinical Success: Further validate the clinical and economic benefits of IntelliSep through continued research and data collection.
  • Advance Early Detection Technologies: Invest in the development of new diagnostic solutions for fast-moving and immune-mediated diseases.

“Sepsis has historically been one of the most challenging and costly conditions for hospitals to manage due to the lack of rapid, objective diagnostic tools. Thankfully, that’s finally changing with IntelliSep, which holds the potential to transform sepsis care in the same way troponin tests did for cardiac care and rapid CT scans did for stroke diagnosis,” said Cytovale CEO Ajay Shah, PhD. “Cytovale is growing at an astounding pace to meet demand from other health systems looking to tackle this deadly condition. The additional investment will enable us to quickly scale across the U.S. with greater agility to serve health systems and their patients.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |